BAMLET in non-prescription products

By November 17, 2020 October 31st, 2021 No Comments

Press Release, Lund November 17, 2020

Hamlet Pharma is currently in discussions with major multinational companies on Letters of Intent including the evaluation- and development of processes for a potential, future commercial use of BAMLET in nonprescription and food products.

BAMLET (bovine α-lactalbumin made lethal to tumour cells) is a molecular complex formed by bovine α-lactalbumin and oleic acid. The broad spectrum of benefits of BAMLET identified by the research group at Lund University and the development of a bovine derived complex to make use of BAMLET more broadly, present a very interesting opportunity also in non-prescription products. Hamlet Pharma is therefore progressing with this opportunity with support of experienced external resources. The discussions with the multinational companies are governed by non-disclosure agreements.

For more information, please contact

Catharina Svanborg, Chairman and founder of Hamlet Pharma, +46-709 42 65 49

Mats Persson, CEO Hamlet Pharma, +46 705 17 67 57

About HAMLET Pharma
HAMLET Pharma, listed on Spotlight, develops drugs based on the unique tumoricidal protein-lipid complex, HAMLET, formed by two natural and harmless molecules found in breast milk. Development focuses primarily on drugs, for the treatment and prevention of cancer. HAMLET kills tumour cells and has proven safe in proof-of-concept studies in animal models. Alpha1H is the synthetic variant of HAMLET, which has enabled development of the agent for clinical trials. Alpha1H kills different types of tumour cells and has demonstrated therapeutic effects on bladder cancer in animal models. Hamlet Pharma has one ongoing Phase I/II clinical trial with Alpha1H in patients with bladder cancer, a costly form of cancer that is difficult to treat, and intends to expand its activities into other types of cancer. The first results from the ongoing clinical Phase I/II study shows no side effects of Alpha1H, indicating that the treatment is safe and well tolerated. Alpha1H also demonstrated clinical efficacy compared with patients who received placebo. In addition, Hamlet Pharma develops BAMLET, which is a molecular complex formed by bovine α-lactalbumin and oleic acid. Data from animal models suggest that local BAMLET treatment may be effective against colon cancer in man.

This information is insider information that Hamlet Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact persons set out above, on November 17, 2020.

Hamlet Pharma

Author Hamlet Pharma

More posts by Hamlet Pharma

Hamlet Pharma AB

Klinikgatan 32
SE-222 42 Lund, Sweden
+46 40 12 25 00